Clinical Trial Update: Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC） [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating TY-302 in combination with Abiraterone for metastatic castration-resistant prostate cancer; the study is not yet recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone (abiraterone)
• TY-302

Snippet

Sponsor: TYK Medicines, Inc | Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING